ClinicalTrials.gg
RecruitingNCT07299981Updated Jul 16, 2026

Quantitative Net Water Uptake as a Predictor of Functional Outcomes After Intravenous Thrombolysis in Acute Ischemic Stroke International Multicenter Observational Retrospective Study

An observational study in Ischemic Stroke and Thrombolysis, sponsored by Sigmund Freud PrivatUniversitat. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Sigmund Freud PrivatUniversitat · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Ischemic Stroke with a site in Austria — 12 open to participants now, 15 under way, 1 of them phase 3. Ischemic Stroke · Austria.

Planned enrollment
11th of 12
200 · median 1,000
Started
2026
with 3 others
Observational
12 of 49
7 open now
Primary completion
2027-04
later than 9 of 14 live
Registered
46th of 49
by date
Lead sponsor
2 of 49
Sigmund Freud PrivatUniversitat

Among the 49 studies in Ischemic Stroke with a site in Austria, this one is the 11th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2026, is one of 12 observational ones, reaches primary completion later than 9 of the 14 other live ones, and was the 46th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

12 of the 49 studies in Ischemic Stroke with a site in Austria are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Ischemic Stroke with a site in Austria, or all of them as a file.
02

Study summary

While the effectiveness of intravenous thrombolysis (IVT) decreases over time, patients show considerable variability in how quickly their ischemic core progresses. Quantitative net water uptake (NWU) has emerged as a biomarker indicating blood-brain barrier disruption and may better reflect the "tissue clock" than time alone. Low NWU is associated with favorable outcomes, whereas high NWU predicts poor outcomes and futile recanalization. The study aims to determine whether NWU measured on initial non-contrast CT is a treatment effect modifier for the IVT therapy.

03

Conditions studied

  • Ischemic Stroke
  • Thrombolysis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged over 18 years with acute ischemic stroke, symptom onset within 24 hours prior to admission and treatment in one of the stroke units of the participating institutions between 2018 and 2025 treated using IVT and fullfilling inclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute ischemic stroke treated with intravenous thrombolysis
  • Imaging with non-contrast cranial CT on admission
  • Follow-up imaging with non-contrast cranial CT or MRI 12-24 hours after IVT
  • Final Infarct volume > 5ml
  • ASPECTS available

Exclusion criteria

Exclusion Criteria:

  • Known use of oral anticoagulation (OAC) on admission
  • Preexisting ischemic infarction on admission non-contrast cranial CT
  • Patients with large vessel occlusion AIS who underwent mechanical thrombectomy
  • Low imaging quality precluding radiological measurements
  • Severe white matter lesions precluding radiological measurements
  • No ASPECTS
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • patients with ischemic stroke receiving IVT

    Other: No Interventions

Interventions

  • OtherNo Interventions

    Not applicable as this is an observational, retrospective study.

06

What researchers measure

Primary outcomes

  1. Number of participants with functional independence (modified Rankin Scale score 0-1)

    Functional independence defined as a modified Rankin Scale (mRS) score of 0-1 assessed at 90 days.

    Time frame: at 90 days

Secondary outcomes

  1. Number of participants with symptomatic intracerebral hemorrhage

    Symptomatic intracerebral hemorrhage (sICH) as defined by the European Cooperative Acute Stroke Study (ECASS) III criteria (i.e., an ICH associated with an increase of ≥4 points on the NIHSS or death where intracranial hemorrhage is the predominant cause of neurological deterioration).

    Time frame: at 24 hours

  2. Number of participants with intracerebral hemorrhage on follow-up brain imaging

    Intracerebral hemorrhage detected on follow-up brain imaging performed within 24 hours after treatment.

    Time frame: at 24 hours

  3. Mortality

    Time frame: at 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results after deidentification

Supporting information: Study protocol, Statistical analysis plan

Access criteria: Data that support the findings of this study will be available from the corresponding author after academic board review and upon reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Apr 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 23, 2025
StartActual
Feb 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07299981
Lead sponsor
Sigmund Freud PrivatUniversitat
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Feb 1, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

Marek Sykora
Contact
marek.sykora@med.sfu.ac.at
+431211215183

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion